Why did EPS grow while revenue declined?

Non-GAAP EPS growth came mainly from cost reductions. Non-GAAP R&D fell about $124 million (roughly 22%) and non-GAAP SG&A fell about $33 million, both attributed to the Fit for Growth and R&D prioritization programs. Cost of sales as a percentage of revenue also improved from 27% to 22%, helped by product mix and the absence of idle capacity charges. Lower revenue is largely due to a 39% drop in contract manufacturing, royalty and other revenue and a 4% decline in MS product revenue.

How is the LEQEMBI launch progressing?

Management reported about $19 million in first-quarter in-market sales, nearly three times the fourth quarter of 2023. Patients on therapy rose about 2.5 times since the end of 2023, and new patient starts increased significantly through March, contributing over 20% of cumulative patients now on therapy. Management described the trajectory as building at a steady pace, but the amount is still small relative to Biogen's overall revenue base.

Is Biogen's full-year 2024 guidance still intact?

Yes. Biogen reaffirmed non-GAAP diluted EPS guidance of $15.00 to $16.00, about 5% growth at the midpoint versus 2023. It continues to expect total revenue to decline by a low- to mid-single digit percentage, core pharmaceutical revenue to be roughly flat, and operating income to grow at a low-double digit percentage with mid-single digit margin improvement. The guidance excludes potential acquisitions, business development deals, pending litigation, and tax or healthcare reform effects.

What is Biogen's balance sheet and capital allocation position?

As of March 31, 2024, Biogen had about $1.1 billion in cash and marketable securities against about $6.5 billion in total debt, for net debt of about $5.5 billion. Free cash flow was $507 million in the quarter. A $750 million portion of the 2023 Term Loan taken on for the Reata acquisition has been repaid, with the remaining $250 million expected in Q2 2024. Biogen received a $437 million installment from Samsung BioLogics after quarter-end and repurchased no shares, leaving $2.1 billion under its authorization.

What are the main risks to the investment case highlighted in the filing?

Key risks include ongoing dependence on MS products, which continue to decline, and the pace of uptake for new launches such as LEQEMBI, SKYCLARYS and ZURZUVAE. SPINRAZA ex-U.S. revenue fell 35% amid competition. Other risks cited include pricing and reimbursement pressure, biosimilar commercialization, intellectual property challenges, indebtedness, foreign exchange exposure, and the potential for unexpected charges or litigation outcomes that are excluded from guidance.

BIIB 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed April 24, 2024. Cited figures are marked; the original filing is the authoritative source.

Biogen's first quarter 2024 results (reported April 24, 2024) show a mixed picture: GAAP diluted EPS rose 1% to $2.70^a and non-GAAP diluted EPS rose 8% to $3.67, but total revenue fell 7% to $2.29 billion and product revenue fell 3% to $1.71 billion.

The earnings improvement was driven by cost discipline rather than top-line growth. Non-GAAP R&D fell about 22% and non-GAAP SG&A fell about 6%, with no idle capacity charges in the quarter (versus roughly $45 million^b in Q1 2023). Contract manufacturing, royalty and other revenue dropped 39%, which accounts for much of the total revenue decline.

Operating income grew 10% on a GAAP basis and 24% on a non-GAAP basis. The new launches are early but showing momentum. LEQEMBI in-market sales were about $19 million^c, nearly triple Q4 2023, and patients on therapy rose roughly 2.5 times since year-end 2023.

SKYCLARYS generated $78 million^d globally, with the E.U. launch now underway, and ZURZUVAE contributed about $12 million. Offsetting these gains, MS product revenue fell 4% and SPINRAZA ex-U.S. revenue fell 35%, reflecting shipment timing and competition. Management reaffirmed full-year 2024 non-GAAP EPS guidance of $15.00 to $16.00 (about 5% growth at the midpoint), while expecting total revenue to decline by a low- to mid-single digit percentage.

The balance sheet remains leveraged. Net debt was about $5.5 billion at quarter-end, against $1.1 billion in cash and $6.5 billion in total debt. Free cash flow was $507 million, and Biogen received about $437 million from Samsung BioLogics after quarter-end.

No shares were repurchased in the quarter, leaving $2.1 billion under the authorization. Investors should weigh the margin and EPS improvement against continued revenue erosion and the pace at which new launches must replace declining MS franchise sales.

02—Key points

Key Highlights

Non-GAAP diluted EPS rose 8% to $3.67 and GAAP diluted EPS rose 1% to $2.70, despite a 7% decline in total revenue to $2.29 billion.
Non-GAAP operating income grew 24% and GAAP operating income grew 10%, supported by Fit for Growth savings and no idle capacity charges (about $45 million in Q1 2023).
LEQEMBI in-market sales reached about $19 million, nearly triple Q4 2023, with patients on therapy up roughly 2.5 times since end-2023.
SKYCLARYS generated $78 million in global revenue and launched in the E.U. during the quarter; ZURZUVAE contributed about $12 million.
MS product revenue fell 4% to $1.08 billion and contract manufacturing, royalty and other revenue fell 39%, the main drivers of top-line decline.
Full-year 2024 non-GAAP EPS guidance of $15.00 to $16.00 was reaffirmed, with total revenue expected to decline by a low- to mid-single digit percentage.
Net debt was about $5.5 billion at March 31, 2024; free cash flow was $507 million and no shares were repurchased in the quarter.

03—Questions

Frequently Asked Questions

Why did EPS grow while revenue declined?
Non-GAAP EPS growth came mainly from cost reductions. Non-GAAP R&D fell about $124 million (roughly 22%) and non-GAAP SG&A fell about $33 million, both attributed to the Fit for Growth and R&D prioritization programs. Cost of sales as a percentage of revenue also improved from 27% to 22%, helped by product mix and the absence of idle capacity charges. Lower revenue is largely due to a 39% drop in contract manufacturing, royalty and other revenue and a 4% decline in MS product revenue.
How is the LEQEMBI launch progressing?
Management reported about $19 million in first-quarter in-market sales, nearly three times the fourth quarter of 2023. Patients on therapy rose about 2.5 times since the end of 2023, and new patient starts increased significantly through March, contributing over 20% of cumulative patients now on therapy. Management described the trajectory as building at a steady pace, but the amount is still small relative to Biogen's overall revenue base.
Is Biogen's full-year 2024 guidance still intact?
Yes. Biogen reaffirmed non-GAAP diluted EPS guidance of $15.00 to $16.00, about 5% growth at the midpoint versus 2023. It continues to expect total revenue to decline by a low- to mid-single digit percentage, core pharmaceutical revenue to be roughly flat, and operating income to grow at a low-double digit percentage with mid-single digit margin improvement. The guidance excludes potential acquisitions, business development deals, pending litigation, and tax or healthcare reform effects.
What is Biogen's balance sheet and capital allocation position?
As of March 31, 2024, Biogen had about $1.1 billion in cash and marketable securities against about $6.5 billion in total debt, for net debt of about $5.5 billion. Free cash flow was $507 million in the quarter. A $750 million portion of the 2023 Term Loan taken on for the Reata acquisition has been repaid, with the remaining $250 million expected in Q2 2024. Biogen received a $437 million installment from Samsung BioLogics after quarter-end and repurchased no shares, leaving $2.1 billion under its authorization.
What are the main risks to the investment case highlighted in the filing?
Key risks include ongoing dependence on MS products, which continue to decline, and the pace of uptake for new launches such as LEQEMBI, SKYCLARYS and ZURZUVAE. SPINRAZA ex-U.S. revenue fell 35% amid competition. Other risks cited include pricing and reimbursement pressure, biosimilar commercialization, intellectual property challenges, indebtedness, foreign exchange exposure, and the potential for unexpected charges or litigation outcomes that are excluded from guidance.

04—Continue

← View all 8-K filings